Benitec Biopharma Inc. Common Stock BNTC
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T14:58:44.154Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T14:30:00.367125226Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T14:58:43.456818+00:00
Benitec Biopharma Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.72 | 721.2% | 54.5% | |||
| 25Δ | 7.73 | 657.0% | 43.8% | |||
| 30Δ | 8.35 | 579.1% | 37.2% | |||
| 35Δ | 8.97 | 501.3% | 30.5% | |||
| 40Δ | 9.59 | 423.5% | 23.9% | |||
| 45Δ | 10.09 | 363.8% | 18.9% | |||
| 50Δ | 18.50 | 772.8% | 123.1% | 10.34 | 338.5% | 17.0% |
| 55Δ | 12.94 | 618.6% | 63.9% | 10.59 | 313.3% | 15.0% |
| 60Δ | 10.42 | 502.2% | 37.0% | 10.85 | 288.0% | 13.1% |
| 65Δ | 9.36 | 433.0% | 26.2% | 11.10 | 262.7% | 11.2% |
| 70Δ | 8.57 | 373.4% | 18.3% | 11.35 | 237.4% | 9.2% |
| 75Δ | 7.79 | 313.8% | 10.5% | 11.61 | 212.1% | 7.3% |
| 80Δ | 7.02 | 301.2% | 6.5% | 11.86 | 186.9% | 5.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.72
- IV
- 721.2%
- B/E move
- 54.5%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.73
- IV
- 657.0%
- B/E move
- 43.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.35
- IV
- 579.1%
- B/E move
- 37.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.97
- IV
- 501.3%
- B/E move
- 30.5%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.59
- IV
- 423.5%
- B/E move
- 23.9%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.09
- IV
- 363.8%
- B/E move
- 18.9%
50Δ
- Pseudo strike
- 18.50
- IV
- 772.8%
- B/E move
- 123.1%
- Pseudo strike
- 10.34
- IV
- 338.5%
- B/E move
- 17.0%
55Δ
- Pseudo strike
- 12.94
- IV
- 618.6%
- B/E move
- 63.9%
- Pseudo strike
- 10.59
- IV
- 313.3%
- B/E move
- 15.0%
60Δ
- Pseudo strike
- 10.42
- IV
- 502.2%
- B/E move
- 37.0%
- Pseudo strike
- 10.85
- IV
- 288.0%
- B/E move
- 13.1%
65Δ
- Pseudo strike
- 9.36
- IV
- 433.0%
- B/E move
- 26.2%
- Pseudo strike
- 11.10
- IV
- 262.7%
- B/E move
- 11.2%
70Δ
- Pseudo strike
- 8.57
- IV
- 373.4%
- B/E move
- 18.3%
- Pseudo strike
- 11.35
- IV
- 237.4%
- B/E move
- 9.2%
75Δ
- Pseudo strike
- 7.79
- IV
- 313.8%
- B/E move
- 10.5%
- Pseudo strike
- 11.61
- IV
- 212.1%
- B/E move
- 7.3%
80Δ
- Pseudo strike
- 7.02
- IV
- 301.2%
- B/E move
- 6.5%
- Pseudo strike
- 11.86
- IV
- 186.9%
- B/E move
- 5.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 204.37% | |
| 231.74% | |
| 249.91% | |
| 270.96% | |
| 133.48% | |
| 141.78% | |
| 143.76% | |
| 144.23% | |
| 148.09% | |
| 150.35% | |
| 161.61% | |
| 160.92% | |
| 157.18% | |
| 163.54% | |
| 163.07% | |
| 180.81% | |
| 191.64% | |
| 196.68% | |
| 203.99% | |
| 238.60% | |
| 275.37% | |
| 155.11% | |
| 162.06% | |
| 161.77% | |
| 186.67% | |
| 194.07% | |
| 197.45% | |
| 198.12% | |
| 207.49% | |
| 239.00% | |
| 251.49% | |
| 258.31% | |
| 278.34% | |
| 281.45% | |
| 317.59% |
Biotechnology
BNTX
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
More →BYSI
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered…
More →CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of T-cell therapies designed for patients with B-cell-mediated autoimmune…
More →CADL
Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform, which uniquely targets…
More →CAI
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The…
More →CAPR
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad…
More →